The USFDA recently is-sued a guideline titled product Launch Notification under Section 506I. The guideline instructs companies to let the USFDA know if a product is not launched even after 180 days of getting approval. USFDA felt the need to issue this guideline on product launch since data shows that only about 40 per cent of generic products are getting launched after USFDA approval within a year. This means about 60 per cent of products are not getting launched after USFDA approval even after a year. The data also shows that even after five years about 30 per cent of products are not getting launched. Pharma companies spend a lot of money on development, bio studies, filing of product and pay GDUFA fees. Then, why are the products not launched even after approval? The answer is that there are way too many competitors marketing the same product thereby reducing the scope of marketing or the cost of the product is prohibitive to selling the product at a competitive price.
Essentially two developments have happened in the last couple of years:
1. The USFDA stepped up approval of products by introducing GDUFA and inducted a lot of new inspectors/reviewers to clear the backlogs of approval. From a backlog of more than 36 months once, one can expect approval of new product now in 12-14 months if the quality of filing and data is acceptable. This helped in more generic products getting approval, throwing the US market into intense competition.
2. The market consolidated in the US and from about 10-12 buyers, today about 90 per cent of buying are controlled effectively by three buyers only, namely – Red Oak, Walgreen- Boots Alliance & McKesson. This means the buyers have now very high bargaining power bringing price pressure on marketed products. It is now a win-win situation for both, the government and consumers in the US.
この記事は Express Pharma の October 2020 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です ? サインイン
この記事は Express Pharma の October 2020 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です? サインイン
Blissfill-Calibrated syringe pipettes for repetitive laboratory dosing as per ISO 8655-9
Blissfill syringe pipettes provide laboratories with an ergonomic, self-refilling solution for repetitive dosing, delivering precise volumes from 0.05ml to 10ml. With ISO 8655-9 compliance and an included calibration certificate, Blissfill ensures accuracy and ease of use for high-demand lab applications
Ensuring pharma compliance with testo data measurement technology
Comprehensive data measurement tools address regulatory demands and secure quality in pharma
Waters launches software for lab-centric business intelligence enabling audit readiness
waters_connect Data Intelligence software provides laboratories with comprehensive business intelligence on their chromatographic data throughout the product development lifecycle, enabling real-time audit readiness and query response, while reducing time spent on audit preparation
Ensuring clean room integrity with Prime Clean Reset High-Speed Doors
Designed with precision to meet the stringent requirements of controlled environments, Prime Clean Reset is the epitome of performance and reliability, ensuring that your clean room operations consistently meet the highest standards of regulatory compliance and product integrity
Optimising efficiency with Remote Laboratory Solutions
LabWare's comprehensive suite of software solutions designed specifically for laboratories offers reliable Remote Laboratory Solutions to help your business thrive in the current climate
Ensuring water quality with the 6000TOCi: The ultimate solution for continuous TOC measurement
The 6000TOCi Sensor is a comprehensive solution that brings together continuous monitoring, rapid response, reliability, and compliance
Enhancing pharmaceutical analysis in critical areas
Dheeraj Handique, Manager GC/GCMS Product Marketing, Shimadzu Analytical (India) highlights the benefits of GCMS-TQ8050 NX with HS-20 NX trap for genotoxic impurities, nitrosamines, and, extractables and leachables
Technical innovations for Annex 1
To meet the stringent EU GMP Annex 1 requirements, Optima presents innovative solutions to improve product and patient safety in pharmaceutical manufacturing. From minimising glove interventions and optimising First Air flow to advanced automation for integrity testing, this article explores how Optima's technologies support compliance in aseptic fill-and-finish processes
JRS Pharma - The Global MCC Manufacturing Network
JRS Pharma is one of the largest manufacturers of MCC across the globe. The know-how is based on more than 25 years of experience in development of own processes
Mack Pharmatech is the first to launch PLC-based environmental chambers in India
Manoj Choudhari, Managing Director, Mack Pharmatech shares insights on his company's pioneering expand globally and enhance regulatory compliance